ESR1 and breast cancer: The AR antagonizes the mitogenic activity of the estrogen receptor [45] suggesting that AR may oppose ERα activity during the early stages of MMTV-NeuNT driven tumorigenesis and AR loss leads to the accelerated onset of mammary tumors.